Curative efficacy of tiragolumab combined with radiofrequency ablation for advanced non-small cell lung cancer
10.3969/j.issn.1008-794X.2025.04.010
- VernacularTitle:替雷利珠单抗联合射频消融术治疗中晚期非小细胞肺癌的疗效
- Author:
Shiyun LUO
1
;
Tangqing FU
;
Tong XIAO
Author Information
1. 610041 四川成都 三六三医院胸外科
- Keywords:
tiragolumab;
CT-guided radiofrequency ablation;
non-small cell lung cancer;
immune function
- From:
Journal of Interventional Radiology
2025;34(4):393-397
- CountryChina
- Language:Chinese
-
Abstract:
Objective To discuss the effect of tiragolumab combined with radiofrequency ablation(RFA)on the immune function in patients with advanced non-small cell lung cancer(NSCLC).Methods A total of 92 patients with advanced NSCLC,who were treated at the Sanliusan Hospital of China from January 2021 to January 2022,were enrolled in this study.Using random digital table method,the patients were divided into observation group and control group,with 46 patients in each group.The patients of the control group received CT-guided RFA combined with chemotherapy,while the patients of the observation group,on the basis of treatment regimen as in the control group,received additional tiragolumab treatment.The duration of one treatment cycle was 21 days,and patients of both groups received 4 cycles of treatment.The clinical efficacy,adverse reactions,and the preoperative and postoperative immune function indicators,tumor markers and lung function indicators were compared between the two groups.The patients were followed up for 2 years,and the progression-free survival(PFS)and survival rate of the patients were recorded.Results The total effective rate in the observation group was higher than that in the control group.The improvement degree of postoperative immune function and pulmonary function indicators in the observation group was higher than that in the control group,meanwhile the postoperative level of tumor markers in the observation group was lower than that in the control group,the differences in the above indexes between the two groups were statistically significant(P＜0.05).No statistically significant difference in the incidence of adverse reactions existed between the two groups(P＞0.05).Follow-up check-ups indicated that PFS and survival rate in the observation group were higher than those in the control group,the differences were statistically significant(P＜0.05).Conclusion For patients with advanced NSCLC,tiragolumab combined with RFA can improve the immune functions,therapeutic efficacy,and survival rate of patients.
